[Chinese guidelines for lipid management (2023)].

doi:10.3760/cma.j.cn112148-20230119-00038

March 24, 2023

[Chinese guidelines for lipid management (2023)].

View at Publisher

Ask AI

Bookmark

Share

Why the study?

With the rising burden of ASCVD in China and recent global research breakthroughs in lipid management, an update to China's lipid guidelines was urgently needed.

Structured PICO

P

Population

Chinese population across the lifespan (from children to elderly) with or at risk for atherosclerotic cardiovascular disease (ASCVD)

I

Intervention

Lipid management targeting LDL-C based on risk stratification, utilizing lifestyle interventions, moderate-intensity statins, cholesterol absorption inhibitors, and/or PCSK9 inhibitors

The 2023 Chinese guidelines for lipid management emphasize risk-stratified LDL-C targets and recommend a step-wise pharmacological approach starting with moderate-intensity statins.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

New Chinese lipid guideline prioritizes risk-stratified LDL-C targets and moderate statins; leaves open need for local outcome validation.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2023 study studied this question.

synapsesocial.com/papers/6a70fc8245e51b8c20274197 https://doi.org/10.3760/cma.j.cn112148-20230119-00038

View at Publisher

Ask AI

Bookmark

Share

[Chinese guidelines for lipid management (2023)].

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

[Chinese guidelines for lipid management (2023)].

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading